Last reviewed · How we verify
Cephacetril (cefacetrile)
Cephacetril (generic name: cefacetrile) is a cefacetrile drug. It is currently in unknown development.
Cephacetril works by blocking the enzymes that bacteria need to build their cell walls, ultimately leading to the death of the bacteria.
Cephacetril, also known as cefacetrile, is a small molecule antibiotic in the cefacetrile class. Its mechanism of action involves inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. However, due to limited information, its target and approved indications are unknown. The commercial status of cephacetril is unclear, and it is not known if it is patented or available as a generic. Key safety considerations include its short half-life of 2.02 hours and negligible bioavailability of 0%.
At a glance
| Generic name | cefacetrile |
|---|---|
| Drug class | cefacetrile |
| Target | Penicillin-binding protein 1A |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like houses, and the bacteria are like construction workers trying to build new houses. Cephacetril is like a construction foreman who stops the workers from building the houses by blocking the tools they need. This prevents the bacteria from growing and multiplying, helping to fight off the infection.
Approved indications
Common side effects
Key clinical trials
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Aminoglycosides in Early Sepsis (PHASE4)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cephacetril CI brief — competitive landscape report
- Cephacetril updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Cephacetril
What is Cephacetril?
How does Cephacetril work?
What is the generic name of Cephacetril?
What drug class is Cephacetril in?
What development phase is Cephacetril in?
What does Cephacetril target?
Related
- Drug class: All cefacetrile drugs
- Target: All drugs targeting Penicillin-binding protein 1A
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing